Both anti-TLSP (tezepelumab) and anti-IL-33 (itepekimab) have reported phase 2 clinical data in asthma: anti-TLSP showing the reduction in the frequency of asthma exacerbations13 and anti-IL-33 provided some protection against loss of asthma control55. The gene discussed is IL33; the disease is asthma.